# MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

> **NCT02422381** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Providence Health & Services** · enrollment: 16 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** MK-3475
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02422381
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-07-20
- **Primary completion:** 2019-01-09
- **Final completion:** 2026-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422381, "MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02422381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*